 Emerging Europe Generics Producers: Where Are the Big Opportunities? provides competitive intelligence on almost 40 leading generics producers (see full list below) operating in 16 key markets: Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kazakhstan, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine.
The Report highlights highlight opportunities for firms such as India’s Ranbaxy, which bought Terapia in 2006 and other Asian firms which are keen to enter this comparatively highly-priced generics market via acquisition-based strategies.
Emerging Europe Generics Producers: Where Are the Big Opportunities? also evaluates key industry trends and growth dynamics, and features BMI’s independent 5-year industry forecasts for each market to end-2012. Each of the 16 generics markets is also ranked according to the competitiveness of the regulatory and business operating environment, and growth potential of the generics segment over the 5-year forecast horizon.
The potential is impressive. BMI values the Emerging Europe generic drug sector at US$19.9bn in 2008, and we forecast 7% year-on-year growth for each of the next three years. The Report examines the key drivers of this solid growth (growing economies, ageing populations and the emergence of chronic diseases), and the opportunities arising for multinational and local generics producers alike in each market.
But growth potential is not uniform across the region. Russia, which accounts for one-third of the market, is by far the most attractive. However, high growth Bulgaria and Kazakhstan – which will both experience double-digit expansion in 2008 – are key markets to watch; in stark contrast to Hungary, where falling prices is a key constraint on growth.
Furthermore, there are risks. New market entrants to Russia and Central Asia must take care to assess opportunities given lax patent laws, which increase the industry’s vulnerability to unauthorised copies.
|
CONTENTS
Chapter 1 - Emerging Europe’s Generic Drug Sector
- Chart: Per Capita Generic Drug Spending In Central And Eastern Europe During 2007 (US$)
- Chart: Central And Eastern Europe Population In 2007 (mn)
- Chart: Generics Drug Sales As Percent Of Total Pharmac eutica l Market Value
- Table: Value Of Central And Eastern Europe’s Generic Drug Markets (UD$mn)
- Table: Pharmaceutical Business Environment Indicators
Chapter 2 - Business Environment Ratings
- Pharmaceutical Ratings - Methodology
- Ratings Overview
- Ratings System
- Indicators
- Weighting
- Bulgaria
- Table: Weighting Of Components
- Table: Pharmac eutica l Business Environment Rankings
- Croatia
- Czech Republic
- Estonia
- Greece
- Hungary
- Kazakhstan
- Latvia
- Lithuania
- Poland
- Romania
- Russia
- Serbia
- Slovakia
- Slovenia
- Ukraine
Chapter 3 - Generics & Branded Drugs Forecasts
- Bulgaria
- Table: Bulgaria’s Generics And Patented Market Forecasts
- Croatia
- Table: Croatia's Generics And Patented Market Forecasts
- Czech Republic
- Table: Czech Republic's Generics And Patented Market Forecasts
- Estonia
- Table: Estonia's Generics And Patented Market Forecasts
- Greece
- Table: Greece's Generics And Patented Market Forecasts
- Hungary
- Table: Hungary's Generics And Patented Market Forecasts
- Kazakhstan
- Table: Kazakhstan's Generics And Patented Market Forecasts
- Latvia
- Table: Latvia's Generics And Patented Market Forecasts
- Lithuania
- Table: Lithuania's Generics And Patented Market Forecasts
- Poland
- Table: Poland's Generics And Patented Market Forecasts
- Romania
- Table: Romania's Generics And Patented Market Forecasts
- Russia
- Russia: Estonia's Generics And Patented Market Forecasts
- Serbia
- Table: Serbia's Generics And Patented Market Forecasts
- Slovakia
- Table: Slovakia's Generics And Patented Market Forecasts
- Slovenia
- Table: Slovenia's Generics And Patented Market Forecasts
- Ukraine
- Table: Ukraine's Generics And Patented Market Forecasts
Chapter 4 - Company Profiles - Bulgaria
- Actavis Bulgaria (formerly Balkanpharma)
- Bivot
Chapter 5 - Company Profiles - Croatia
Chapter 6 - Company Profiles - Czech Republic
- Zentiva (incorporating Sicomed)
Chapter 7 - Company Profiles - Estonia
- Grindeks (includes Tallinn Pharmaceutical Plant)
Chapter 8 - Company Profiles - Greece
- Vianex
- Lavipharm
- Gerolymatos SA
- Genepharm
- Pharmathen Pharmaceuticals
- Kleva
Chapter 9 - Company Profiles - Hungary
- Gedeon Richter
- Egis Pharmaceuticals (Servier)
- Krka
Chapter 10 - Company Profiles - Kazakhstan
Chapter 11 - Company Profiles - Lithuania
Chapter 12 - Company Profiles - Poland
Chapter 13 - Company Profiles - Romania
- Zentiva (incorporating Sicomed)
Chapter 14 - Company Profiles - Russia
Chapter 15 - Company Profiles - Serbia
Chapter 16 - Company Profiles - Slovakia
- Zentiva (incorporating Sicomed)
Chapter 17 - Company Profiles - Lek
- Zentiva (incorporating Sicomed)
Chapter 18 - Company Profiles - Ukraine
Key Benefits of the Report
-
Identify and evaluate the scale of growth opportunities across 16 key markets for generics producers – including small, growing and little understood markets
-
Benchmark competitors and peers in each market using recently researched company profiles, featuring latest intelligence on almost 40 generics companies, analysing competitive positioning, opportunities, risks and strategies of each company
-
Benchmark your own views and forecasts for market performance against BMI’s independent 5-year industry forecasts for generics and patented drugs
-
Use BMI’s country-comparative business environment ratings to assess the operating risks, opportunities and key factors impacting corporate profitability in each of the 16 markets covered
Why you need to order this report today:
Strategists
Gain an insight into the commercial opportunities available in Emerging Europe’s generics market, using our clearly-explained medium-term economic forecasts (2008-2012) to benchmark your own growth projections.
Risk Managers
Discover the key Industry, Political, Economic and Operational risks facing companies in these rapidly developing states, and exploit BMI’s quantitatively-based risk assessment model to stress-test your own assumptions.
Country Managers
Gain an insight into the country-specific growth trajectories and the key strengths of your clients and competitors.
Financial Planners
Critically evaluate the assumptions underpinning your medium-term financial projections using BMI’s growth projections for the future direction and value of the currency and key domestic interest rates; the principal determinant of business investment and consumer spending growth. |
